Dynavax Technologies | DVAX - Actif À Court Terme



Actif À Court Terme Changement Date
AbbVie USD 29.06B 523M 2025-12
Adma Biologics USD 466.51M 63.86M 2025-12
Agenus USD 133.44M 514K 2025-12
Amgen USD 29.06B 1.17B 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
Biogen USD 8.97B 37.5M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Gilead Sciences USD 19.89B 1.05B 2025-12
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Merck USD 47.56B 10.49B 2025-09
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 281.36M 94.79M 2025-09
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
TG Therapeutics USD 630.76M 31M 2025-12
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12